Related Experiment Videos
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX
1Department of Biochemistry and Molecular Biology, University of Leeds, U.K.
Summary
Mammalian cell-surface peptidases like neutral endopeptidase (NEP) and endothelin-converting enzyme (ECE) process important peptides. Inhibitors of these peptidases show promise for treating cardiovascular and renal diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Mammalian cell-surface peptidases are crucial for neuropeptide and peptide hormone metabolism.
- Neutral endopeptidase-24.11 (NEP) and endothelin-converting enzymes (ECE) are key zinc metallopeptidases with structural similarities to bacterial enzymes.
- KELL and PEX proteins show homology to NEP but lack identified enzymatic activity.
Purpose of the Study:
- To review the roles of NEP and ECE in peptide processing.
- To highlight the significance of NEP substrates like enkephalins and atrial natriuretic peptides.
- To discuss the involvement of ECE in endothelin biosynthesis and its implications in cardiovascular conditions.
Main Methods:
- Literature review of mammalian peptidases, focusing on NEP and ECE.
- Analysis of enzyme structures and substrate specificities.
- Examination of the physiological and pathological roles of these enzymes and their products.
Main Results:
- NEP processes significant neuropeptides, including enkephalins and atrial natriuretic peptides.
- ECE catalyzes the final step in endothelin biosynthesis, primarily in endothelial cells.
- ECE-1 is implicated in smooth muscle proliferation and atherosclerosis development.
- Homologous proteins KELL and PEX await substrate identification.
Conclusions:
- NEP and ECE are vital cell-surface peptidases with diverse roles in peptide metabolism.
- ECE-1's role in endothelin-1 production links it to cardiovascular pathologies like atherosclerosis.
- Inhibitors targeting ECE and NEP hold potential therapeutic value in cardiovascular and renal medicine.